Corcept Therapeutics Incorporated

CORT | News | $22.48 -2.26% -2.31% 1.1M

(0.0% 1d) (-6.7% 1m) (3.4% 1y) (0.0% 2d) (3.1% 3d) (0.5% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 2,339,782,356
http://www.corcept.com
Sec Filling | Patents | 206 employees

(United States) Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

hormone metabolic

add to watch list Paper trade email alert is off

Press-releases

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
CORT | News | $22.48 -2.26% -2.31% 1.1M

Health Technology

| Email alert Add to watchlist
first conference update therapeutics financial

Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
Published: 2024-04-22 (Crawled : 12:00) - globenewswire.com
CORT | News | $22.48 -2.26% -2.31% 1.1M

Health Technology

| 0.48% | O: -6.86% H: 6.89% C: 4.6%
positive trial results

Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
CORT | News | $22.48 -2.26% -2.31% 1.1M

Health Technology

| -2.54% | O: -0.42% H: 0.55% C: -1.49%
sclerosis trial

Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
CORT | News | $22.48 -2.26% -2.31% 1.1M

Health Technology

| -7.63% | O: 2.41% H: 0.0% C: -4.98%
cancer trial

Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
CORT | News | $22.48 -2.26% -2.31% 1.1M

Health Technology

| -9.84% | O: -0.82% H: 2.96% C: 1.74%
trial

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
Published: 2024-03-06 (Crawled : 13:00) - globenewswire.com
VXRT | News | $0.7051 -5.41% -5.72% 1.5M

Health Technology

| -35.95% | O: -0.83% H: 3.33% C: 0.0%
CORT | News | $22.48 -2.26% -2.31% 1.1M

Health Technology

| -0.78% | O: 2.46% H: 0.0% C: -3.03%

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
Published: 2024-02-15 (Crawled : 21:00) - globenewswire.com
CORT | News | $22.48 -2.26% -2.31% 1.1M

Health Technology

| -5.97% | O: 6.3% H: 0.0% C: -12.65%
update therapeutics financial results

Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
Published: 2024-02-15 (Crawled : 21:00) - globenewswire.com
CORT | News | $22.48 -2.26% -2.31% 1.1M

Health Technology

| -5.97% | O: 6.3% H: 0.0% C: -12.65%
trial results

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
Published: 2024-02-08 (Crawled : 21:00) - globenewswire.com
CORT | News | $22.48 -2.26% -2.31% 1.1M

Health Technology

| 2.27% | O: 0.71% H: 1.77% C: 1.59%
conference update therapeutics financial

Levi & Korsinsky, LLP Announces a Proposed Settlement in the Corcept Therapeutics Incorporated Securities Litigation
Published: 2024-02-05 (Crawled : 15:00) - prnewswire.com
CORT | News | $22.48 -2.26% -2.31% 1.1M

Health Technology

| 6.58% | O: -0.51% H: 2.42% C: 0.0%
VNET | $1.59 7.43% 6.92% 540K

Technology Services

| -0.34% | O: -1.01% H: 3.4% C: -3.4%
therapeutics

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000950170-24-044185	4	2024-04-12	2024-04-10	Sell	M	30000	0
0000950170-24-044185	4	2024-04-12	2024-04-10	Buy	J	27806	1212614
0000950170-24-044185	4	2024-04-12	2024-04-10	Sell	F	2194	27806
0000950170-24-044185	4	2024-04-12	2024-04-10	Buy	M	30000	30000
0000950170-24-042725	4	2024-04-08	2024-04-04	Sell	M	5443	37224
0000950170-24-042725	4	2024-04-08	2024-04-04	Sell	S	5443	7314
0000950170-24-042725	4	2024-04-08	2024-04-04	Buy	M	5443	12757
0000950170-24-038530	4	2024-03-29	2024-03-27	Sell	M	25953	91986
0000950170-24-038530	4	2024-03-29	2024-03-27	Sell	S	25953	85222
0000950170-24-038530	4	2024-03-29	2024-03-27	Buy	M	25953	111175